Viatris
VTRS
$17.49
-0.29%
Viatris Inc. is a global healthcare company formed in November 2020 through the combination of Pfizer's Upjohn off-patent drug business and Mylan, making it one of the world's largest generic and specialty pharmaceutical manufacturers, with operations spanning more than 165 countries. The company's portfolio is split between a roughly 40% generics and biosimilars business and a 60% legacy brands franchise that includes household names such as Lipitor, Norvasc, Lyrica, and Viagra, with management targeting dermatology, ophthalmology, and gastroenterology as key future innovation pillars. The current investor narrative centers on a dramatic turnaround: after a multi-year restructuring, divestiture program, and debt-reduction campaign, the stock has rallied sharply over the past year as investors rotate back into deep-value healthcare names with stable cash flows and a high dividend yield. Debate now hinges on whether Viatris can stabilize its eroding base-business revenue, execute on complex generics and biosimilar launches, and convert its substantial free cash flow into sustainable per-share value, or whether the legacy portfolio's decline will ultimately overwhelm the company's pipeline and cost-cutting efforts.…
VTRS
Viatris
$17.49
Investment Opinion: Should I buy VTRS Today?
Based on the synthesis of data, Viatris earns a Hold rating with a slight bullish tilt. The core thesis is that the company is a deep-value turnaround play with a sustainable 3.85% dividend yield and a revenue inflection that could drive multiple expansion, but negative earnings and high leverage limit near-term upside. The analyst consensus rating of 'buy' (mean 2.0) and average target of $19.40 imply 10.2% upside, which is modest given the risks.
The supporting evidence includes: (1) revenue growth of 4.88% YoY in Q2 2026, the first positive growth in years; (2) a forward PE of 6.58x, well below the sector average; (3) free cash flow of $1.8731 billion TTM, covering the dividend and debt reduction; and (4) a price-to-book ratio of 0.99x, near the low end of its historical range. However, the net margin of -3.16% and negative ROE of -23.89% highlight operational challenges. The dividend yield of 3.85% is attractive but not covered by earnings.
The biggest risks that could invalidate the thesis are: (1) a reversal in revenue growth, (2) a dividend cut if free cash flow declines, and (3) failure to reduce debt. The rating would upgrade to Buy if revenue growth accelerates above 5% and operating margins turn positive, or downgrade to Sell if revenue declines again and free cash flow falls below $1.5 billion. Relative to its history and peers, the stock appears undervalued on a cash flow basis but fairly valued on earnings due to negative net income. The valuation verdict is undervalued relative to peers but with justified caution.
Sign up to view all
VTRS 12-Month Price Forecast
Viatris presents a classic deep-value turnaround with a sustainable dividend and improving revenue, but negative earnings and high leverage temper enthusiasm. The stock's 74% rally over the past year has already captured much of the easy gains, and the average analyst target implies only 10% upside. The base case (55% probability) sees the stock trading in the $18-$21 range as the company executes on its plan. A bullish stance would be warranted if revenue growth accelerates above 5% and margins turn positive; a bearish stance if revenue declines resume or free cash flow deteriorates. Given the balanced risk/reward, a neutral stance with a medium confidence is appropriate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viatris's 12-month outlook, with a consensus price target around $19.70 and implied upside of +12.6% versus the current price.
Average Target
$19.70
0 analysts
Implied Upside
+12.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$13 - $26
Analyst target range
Viatris is covered by 10 analysts, with a consensus recommendation of "buy" (recommendation mean of 2.0 on a scale where lower is more bullish) and an average price target of $19.40, which implies approximately 10.2% upside from the current price of $17.60. The consensus leans moderately bullish, supported by recent institutional actions: Argus Research reiterated a Buy rating on September 8, 2026, Barclays maintained Overweight on May 19, 2026, and Truist Securities reiterated Buy on May 8, 2026, while Piper Sandler and JP Morgan remain Neutral. The presence of both Buy and Neutral ratings, with no Sell ratings, suggests analysts see limited downside but are divided on the pace of the fundamental turnaround.
The target price range is wide, spanning from a low of $13.00 to a high of $25.00, which signals significant disagreement about the company's trajectory. The high target of $25.00 implies roughly 42% upside and likely assumes successful execution on the generics and biosimilars pipeline, continued debt reduction, and multiple expansion as earnings normalize toward the $3.07 forward EPS estimate. The low target of $13.00, about 26% below the current price, likely prices in margin compression, further erosion of the legacy brand portfolio, and the risk that the recent revenue stabilization proves temporary. The wide spread, combined with the fact that the average target of $19.40 is only modestly above the current price, indicates that while the consensus is constructive, conviction is not uniform, and the stock's recent strong run has already captured much of the analysts' expected upside.
Drowning in data?
Find the real signal!
Bulls vs Bears: VTRS Investment Factors
The bull case rests on a nascent revenue recovery (Q2 2026 +4.88% YoY), deep-value multiples (forward PE 6.58x, P/B 0.99x), robust free cash flow ($1.87 billion TTM), and a consensus buy rating with a $19.40 average target. The bear case centers on persistent negative earnings (net margin -3.16%), heavy reliance on declining legacy brands (64% of revenue), high leverage (D/E 0.999), and a dividend that is not covered by earnings. Currently, the bull evidence appears stronger because the revenue inflection and cash flow generation are tangible, and the stock's low beta (0.883) suggests the rally is fundamentally driven. However, the single most important tension is whether the 4.88% revenue growth is sustainable or merely a temporary blip; if the legacy portfolio resumes its decline, the entire investment thesis collapses. Conversely, if Viatris can string together several quarters of growth and expand margins, the valuation gap to peers could close dramatically.
Bullish
- Revenue returns to growth: Q2 2026 revenue of $3.7568 billion grew 4.88% year-over-year, the first meaningful top-line expansion after years of decline, signaling that the legacy brand erosion may finally be reaching a floor. Sequentially, revenue rose from $3.517 billion in Q1 2026, confirming positive momentum.
- Deep value on forward earnings: The forward PE of 6.58x is a fraction of the 15-20x commanded by large-cap pharmaceutical peers, and the price-to-book ratio of 0.99x means the stock trades at roughly book value. If the company hits the $3.07 forward EPS estimate, shares would be valued at just 5.7x forward earnings.
- Strong free cash flow covers dividend: Trailing twelve-month free cash flow of $1.8731 billion comfortably covers quarterly dividend payments of roughly $139.8 million, supporting a 3.85% dividend yield. This cash generation also funded $922.2 million of debt repayment in Q2 2026, reducing leverage.
- Analyst consensus sees upside: With 10 analysts covering the stock, the consensus recommendation is 'buy' (mean 2.0) and the average price target of $19.40 implies 10.2% upside from the current $17.60. Recent reiterations from Argus Research (Buy, Sept 8, 2026), Barclays (Overweight, May 19, 2026), and Truist (Buy, May 8, 2026) reinforce the constructive view.
Bearish
- Negative earnings and thin operating margin: Q2 2026 net income was -$118.8 million (EPS -$0.10) with a net margin of -3.16%, and operating income was just $6.3 million against $1.4502 billion in operating expenses. The company is essentially breaking even at the operating line, leaving little cushion for any revenue shortfall.
- Legacy brand concentration risk: The Brands business generated $2.4184 billion (64% of revenue) in Q2 2026 versus $1.3275 billion from Generics, meaning the company remains heavily dependent on a portfolio of off-patent drugs like Lipitor and Norvasc that face ongoing price erosion and competition. This concentration exposes Viatris to faster-than-expected declines in these mature products.
- High leverage and negative returns: The debt-to-equity ratio of 0.999 and negative ROE of -23.89% highlight a leveraged balance sheet with poor returns on capital. Although free cash flow is strong, the cash balance fell from $1.8042 billion to $890 million in Q2 2026 as debt repayment consumed liquidity.
- Dividend funded from cash flow, not earnings: With a payout ratio of -15.97% and negative trailing EPS of -$0.24, the dividend is being paid out of cash flow rather than earnings. If free cash flow generation falters due to revenue weakness or restructuring costs, the dividend could be at risk.
VTRS Technical Analysis
Viatris is in a powerful, sustained uptrend, with the shares up 74.09% over the trailing twelve months and 41.25% year-to-date, dramatically outperforming the S&P 500's 15.01% and 12.86% respective gains. At a current price of $17.60, the stock is trading at approximately 95.5% of its 52-week range (low of $9.69, high of $18.43), positioning it just below its yearly peak and signaling strong momentum rather than deep-value territory. This near-high positioning means the easy money from the recovery trade has largely been made, and the risk/reward now skews toward whether the stock can break out to new highs or is due for a mean-reversion pullback after such an extended run.
Short-term momentum remains constructive but is decelerating relative to the longer-term trend: the stock is up 2.98% over the past month and 5.39% over three months, versus the 74.09% one-year gain, indicating the explosive phase of the rally has given way to a steadier grind higher. Notably, the 1-month relative strength versus SPY is +2.39 percentage points and the 3-month relative strength is +2.05 points, so Viatris continues to outperform the market even as the pace moderates. The 6-month change of 30.95% and YTD gain of 41.25% confirm the trend is intact, but the recent consolidation between roughly $16.00 and $18.43 suggests the stock is digesting its gains and building a base for a potential breakout.
Key technical levels are well defined: immediate resistance sits at the 52-week high of $18.43, and a decisive breakout above that level on strong volume would signal a continuation of the primary uptrend and likely draw momentum buyers. Support is anchored at the 52-week low of $9.69, though more relevant near-term support lies in the $16.00-$16.50 zone where the stock repeatedly found buyers in August and September; a breakdown below that area would threaten the uptrend structure. With a beta of 0.883, Viatris is roughly 12% less volatile than the broader market, which is unusual for a stock that has nearly doubled off its lows and suggests the rally has been driven by fundamental re-rating rather than speculative excess, though the 5.54 short ratio indicates a meaningful short base that could fuel further upside on a breakout.
Beta
0.86
0.86x market volatility
Max Drawdown
-19.6%
Largest decline past year
52-Week Range
$10-$18
Price range past year
Annual Return
+72.5%
Cumulative gain past year
| Period | VTRS Return | S&P 500 |
|---|---|---|
| 1m | +3.6% | +0.9% |
| 3m | +7.0% | +3.4% |
| 6m | +29.8% | +14.4% |
| 1y | +72.5% | +16.2% |
| ytd | +40.4% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTRS Fundamental Analysis
Viatris's revenue trajectory is showing tentative stabilization after years of decline, with Q2 2026 revenue of $3.7568 billion growing 4.88% year-over-year, a marked improvement from the $3.5821 billion reported in Q2 2025. Sequentially, revenue rose from $3.517 billion in Q1 2026 to $3.7568 billion in Q2 2026, and the segment mix shows the Brands business generating $2.4184 billion versus $1.3275 billion from Generics, meaning the legacy brand portfolio remains the dominant revenue driver even as management emphasizes generics and biosimilars for future growth. The modest return to growth is a critical inflection point for the investment case, as it suggests the erosion of the legacy portfolio may finally be reaching a floor, though the 4.88% growth rate is far from the robust expansion needed to justify a premium multiple.
Profitability remains the company's Achilles' heel: Q2 2026 net income was -$118.8 million, translating to a net margin of -3.16% and an EPS of -$0.10, while the gross margin of 38.77% is respectable for a generic manufacturer but well below the 60-80% range typical of innovative pharmaceutical peers. The quarterly results are highly volatile, swinging from net income of $176.4 million in Q1 2026 to a loss in Q2 2026, and the trailing twelve-month picture is clouded by a massive $3.042 billion loss in Q1 2025 tied to impairments and restructuring charges. Operating income of just $6.3 million in Q2 2026, against $1.4502 billion in operating expenses and $120.7 million in interest expense, shows how thin the margin for error is; the company is essentially breaking even at the operating line, and any revenue softness would quickly push it back into meaningful losses.
On the balance sheet and cash flow front, Viatris generates substantial free cash flow of $1.8731 billion on a trailing twelve-month basis, which comfortably covers its dividend payments of roughly $139.8 million per quarter and provides capacity for debt reduction, as evidenced by $922.2 million of debt repayment in Q2 2026. The debt-to-equity ratio of 0.999 and current ratio of 1.30 indicate a leveraged but manageable capital structure, while the cash balance fell from $1.8042 billion to $890 million during Q2 2026 as the company prioritized debt paydown. However, the negative ROE of -23.89% and ROA of 2.67% highlight that returns on capital remain deeply depressed, and with a payout ratio of -15.97% and a dividend yield of 3.85%, the dividend is being funded from cash flow rather than earnings, which is sustainable only if free cash flow generation holds up.
Quarterly Revenue
$3.8B
2026-06
Revenue YoY Growth
+4.9%
YoY Comparison
Gross Margin
38.8%
Latest Quarter
Free Cash Flow
$1.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTRS Overvalued?
Because Viatris reported negative trailing net income (EPS of -$0.24 and a trailing PE of -4.15x), the PE ratio is not a meaningful primary metric; instead, the price-to-sales ratio of 1.02x is the most appropriate valuation anchor, supplemented by the forward PE of 6.58x, which reflects the market's expectation that earnings will normalize. The enormous gap between the negative trailing PE and the positive forward PE of 6.58x implies the market is pricing in a sharp earnings recovery, consistent with analyst estimates of $3.07 in forward EPS, and the EV/Sales of 2.18x provides a cross-check on the enterprise value relative to the revenue base.
Relative to the broader Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, Viatris trades at a significant discount: a PS ratio of 1.02x is well below the sector's typical range, and the forward PE of 6.58x is a fraction of the 15-20x forward multiples commanded by large-cap pharmaceutical peers. The price-to-book ratio of 0.99x means the stock trades at roughly book value, a classic deep-value signature, while the price-to-cash-flow ratio of 6.29x and EV/EBITDA of -70.63x (distorted by negative trailing EBITDA) further illustrate how depressed the valuation is on most metrics. This discount is partly justified by the company's negative net margin of -24.58%, negative operating margin of -18.62%, and the structural decline of its legacy brand portfolio, but if the revenue stabilization seen in Q2 2026 proves durable, the valuation gap offers substantial re-rating potential.
Historically, Viatris has traded at persistently low multiples: the PS ratio ranged from roughly 2.92x to 4.92x over the past several quarters, and the current 1.02x reading is near the bottom of that band, while the price-to-book ratio of 0.99x compares to historical readings as low as 0.55x and as high as 1.30x. The forward PE of 6.58x is near the low end of the stock's own historical range, suggesting the market is pricing in highly pessimistic expectations despite the recent rally. If the company can deliver on its forward EPS estimate of $3.07, the stock would be trading at just 5.7x forward earnings, a valuation that would be difficult to sustain if growth and margins stabilize, making the current level a potential value opportunity rather than a value trap.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-70.6x
Enterprise Value Multiple
Investment Risk Disclosure
Viatris faces significant financial and operational risks. The company reported a net loss of $118.8 million in Q2 2026, with a net margin of -3.16% and operating income of just $6.3 million, leaving virtually no cushion if revenue disappoints. Its debt-to-equity ratio of 0.999 and interest expense of $120.7 million per quarter consume a large portion of operating cash flow, and the cash balance dropped from $1.8042 billion to $890 million in Q2 2026 as debt was repaid. Additionally, the dividend payout ratio of -15.97% indicates that dividends are funded from cash flow rather than earnings, which is sustainable only as long as free cash flow remains robust. The concentration in legacy brands (64% of revenue) exposes the company to accelerated erosion from generic competition and pricing pressure.
Market and competitive risks are also prominent. The stock trades at a forward PE of 6.58x, a steep discount to large-cap pharma peers (15-20x), but this discount is partly justified by negative net margins and a declining legacy portfolio. If the revenue stabilization proves temporary, the valuation could compress further. The beta of 0.883 indicates lower volatility than the market, but the stock has already rallied 74.09% over the past year, and any market rotation away from deep-value healthcare names could trigger a pullback. The wide analyst target range ($13-$25) reflects uncertainty, and the absence of recent news suggests limited near-term catalysts to sustain momentum. Regulatory headwinds, such as drug pricing reforms or generic competition, could also pressure results.
In a worst-case scenario, a resumption of revenue declines combined with margin compression could push the stock back toward its 52-week low of $9.69, representing a 45% decline from the current $17.60. The analyst low target of $13.00 implies a 26% downside, and the historical max drawdown of -19.65% shows the stock is capable of sharp declines. If free cash flow deteriorates and the dividend is cut, the stock could lose its income appeal, triggering a sell-off. Investors could lose 26% to 45% in such an adverse scenario, depending on the severity of the operational deterioration.
FAQ
The key risks include: 1) Financial risk: negative net margin of -3.16% and high debt-to-equity of 0.999, with interest expense of $120.7 million per quarter. 2) Operational risk: heavy reliance on legacy brands (64% of revenue) that face ongoing price erosion and competition. 3) Dividend risk: payout ratio of -15.97% means the dividend is not covered by earnings and could be cut if free cash flow declines. 4) Market risk: the stock has rallied 74% in a year and trades near its 52-week high, making it vulnerable to a pullback; beta of 0.883 indicates lower volatility but the stock is still subject to sector rotation. The most severe risk is a resumption of revenue declines, which could push the stock toward the analyst low target of $13 or the 52-week low of $9.69.
Our 12-month forecast for VTRS includes three scenarios: Bull case (25% probability) targets $22-$25, assuming successful new product launches and margin expansion. Base case (55% probability) targets $18-$21, assuming steady execution and low-single-digit revenue growth. Bear case (20% probability) targets $13-$15, assuming revenue declines resume and free cash flow deteriorates. The most likely scenario is the base case, with the stock trading around the analyst average target of $19.40. The key assumption is that revenue growth remains positive and the company continues to reduce debt. However, the wide analyst target range ($13-$25) reflects significant uncertainty, and investors should monitor quarterly results closely.
VTRS appears undervalued on most metrics. The forward PE of 6.58x is a fraction of the 15-20x typical for large-cap pharmaceutical peers, and the price-to-book ratio of 0.99x means it trades at roughly book value. The price-to-sales ratio of 1.02x is near the low end of its historical range (2.92x-4.92x), and the price-to-cash-flow ratio of 6.29x is also low. However, the negative trailing PE of -4.15x reflects the company's current unprofitability, and the EV/EBITDA of -70.63x is distorted by negative EBITDA. The market is pricing in a successful turnaround, with forward EPS of $3.07, but if that estimate is not met, the stock could be fairly valued or even overvalued. Relative to its own history and peers, the stock is undervalued, but the discount is partly justified by its risk profile.
VTRS presents a mixed risk/reward profile. On the positive side, the stock trades at a deep discount with a forward PE of 6.58x and a P/B of 0.99x, offers a 3.85% dividend yield, and has a consensus buy rating with a $19.40 average target implying 10.2% upside. However, the company reported a net loss of $118.8 million in Q2 2026, has a negative net margin of -3.16%, and carries a debt-to-equity ratio of 0.999. The stock has already rallied 74% over the past year, leaving less room for error. For income-focused investors with a long horizon, the dividend and cash flow may be attractive, but for those seeking growth, the risks may outweigh the rewards. It is a good buy only for investors comfortable with a turnaround story and willing to accept potential downside to $13 or lower.
VTRS is more suitable for a medium-to-long-term investment horizon (at least 2-3 years) given its turnaround nature and high dividend yield. The stock's beta of 0.883 indicates lower volatility than the market, but it has shown significant price swings, with a max drawdown of -19.65% and a 52-week range of $9.69 to $18.43. Short-term trading could be risky due to the lack of near-term catalysts and the stock's recent rally. Long-term investors can benefit from the 3.85% dividend yield and potential multiple expansion if the company successfully stabilizes revenue and improves margins. However, the dividend is not covered by earnings, so income investors should monitor free cash flow. A minimum holding period of 2-3 years is suggested to allow the turnaround to fully play out.